{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:53:26Z","timestamp":1791928406129,"version":"4.3.4"},"reference-count":272,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400479"],"award-info":[{"award-number":["82400479"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Project of Zhejiang Chinese Medical University","award":["2025RCZXZK47"],"award-info":[{"award-number":["2025RCZXZK47"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD), the recently introduced terminology superseding non-alcoholic fatty liver disease (NAFLD), has emerged as the most prevalent chronic liver condition globally. This multisystem disorder, driven by systemic insulin resistance (IR) and metabolic dysregulation, not only progresses to cirrhosis and hepatocellular carcinoma (HCC) but also substantially increases the risk of cardiovascular disease (CVD), type 2 diabetes (T2D), and extrahepatic malignancies.\u00a0Despite the recent FDA approval of resmetirom for a subset of patients with advanced fibrosis,\u00a0effective pharmacological therapies for the broad MASLD population remain a critical unmet need, underscoring the urgency of continued research into disease mechanisms and therapeutic targets. This review synthesizes recent advances in three interconnected domains:\u00a0the complex pathogenesis of MASLD (including lipotoxicity, mitochondrial dysfunction, inflammation, and fibrogenesis), the evolving landscape of non-invasive diagnostic tools, and the development of novel therapeutic agents targeting key pathways.\u00a0By critically analyzing both successful late-stage trials and instructive failures, we highlight the challenges of translating mechanistic insights into clinically meaningful outcomes. By providing a comprehensive, integrated overview of current knowledge and future directions, this review aims to serve as a valuable resource for researchers and clinicians working toward effective, personalized interventions for this global health challenge.<\/jats:p>","DOI":"10.1186\/s43556-026-00486-5","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:50:37Z","timestamp":1780109437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options"],"prefix":"10.1186","volume":"7","author":[{"given":"Ruizhe","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8688-9925","authenticated-orcid":false,"given":"Xiyang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"486_CR1","first-page":"476","volume":"1","author":"T Addison","year":"1836","unstructured":"Addison T. Observations on fatty degeneration of the liver. Guys Hosp Rep. 1836;1:476\u201385.","journal-title":"Guys Hosp Rep"},{"issue":"7","key":"486_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","volume":"55","author":"J Ludwig","year":"1980","unstructured":"Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434\u20138.","journal-title":"Mayo Clin Proc"},{"key":"486_CR3","first-page":"283","volume":"8","author":"F Schaffner","year":"1986","unstructured":"Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283\u201398.","journal-title":"Prog Liver Dis"},{"issue":"2","key":"486_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","volume":"53","author":"V Ratziu","year":"2010","unstructured":"Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD\/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53(2):372\u201384. https:\/\/doi.org\/10.1016\/j.jhep.2010.04.008.","journal-title":"J Hepatol"},{"issue":"7","key":"486_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312.","journal-title":"Gastroenterology"},{"issue":"3","key":"486_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023;32(3):197\u2013213. https:\/\/doi.org\/10.7570\/jomes23052.","journal-title":"J Obes Metab Syndr"},{"issue":"6","key":"486_CR7","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"issue":"5","key":"486_CR8","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","volume":"169","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Zelber-Sagi S, Lazarus JV, Wong VW, Yilmaz Y, Duseja A, et al. Global consensus recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and steatohepatitis. Gastroenterology. 2025;169(5):1017-32.e2. https:\/\/doi.org\/10.1053\/j.gastro.2025.02.044.","journal-title":"Gastroenterology"},{"issue":"1","key":"486_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, Wong VWS, Rinella ME, Boursier J, Lazarus JV, Yki-J\u00e4rvinen H, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease in adults. Nat Rev Dis Primers. 2025;11(1):14. https:\/\/doi.org\/10.1038\/s41572-025-00599-1.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"486_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.70136","volume":"43","author":"X Fang","year":"2025","unstructured":"Fang X, Xu C, Lu J, Zhuang R, Xu X, Wei X. Lean Metabolic Dysfunction-Associated Steatotic Liver Disease: a wolf in sheep\u2019s clothing. Cell Biochem Funct. 2025;43(11):e70136. https:\/\/doi.org\/10.1002\/cbf.70136.","journal-title":"Cell Biochem Funct"},{"issue":"2","key":"486_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2025.19615","volume":"335","author":"H Tilg","year":"2026","unstructured":"Tilg H, Petta S, Stefan N, Targher G. Metabolic dysfunction-associated steatotic liver disease in adults: A review. JAMA. 2026;335(2):163\u201374. https:\/\/doi.org\/10.1001\/jama.2025.19615.","journal-title":"JAMA"},{"issue":"Suppl","key":"486_CR12","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S32-s50. https:\/\/doi.org\/10.3350\/cmh.2024.0431.","journal-title":"Clin Mol Hepatol"},{"issue":"22","key":"486_CR13","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1097\/cm9.0000000000003517","volume":"138","author":"Y Wang","year":"2025","unstructured":"Wang Y, Huang X, Ye S, Li T, Huang Y, Cheryala M, et al. Global burden of metabolic-associated fatty liver disease: A systematic analysis of Global Burden of Disease Study 2021. Chin Med J (Engl). 2025;138(22):2947\u201354. https:\/\/doi.org\/10.1097\/cm9.0000000000003517.","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"486_CR14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3350\/cmh.2022.0239","volume":"28","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical Bayesian approach. Clin Mol Hepatol. 2022;28(4):841\u201350. https:\/\/doi.org\/10.3350\/cmh.2022.0239.","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"486_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","volume":"79","author":"MH Le","year":"2023","unstructured":"Le MH, Le DM, Baez TC, Wu Y, Ito T, Lee EY, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;79(2):287\u201395. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.040.","journal-title":"J Hepatol"},{"issue":"4","key":"486_CR16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"F Zhou","year":"2019","unstructured":"Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis. Hepatology. 2019;70(4):1119\u201333. https:\/\/doi.org\/10.1002\/hep.30702.","journal-title":"Hepatology"},{"issue":"5","key":"486_CR17","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology. 2020;71(5):1851\u201364. https:\/\/doi.org\/10.1002\/hep.31150.","journal-title":"Hepatology"},{"issue":"1","key":"486_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/s2468-1253(22)00317-x","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20\u201330. https:\/\/doi.org\/10.1016\/s2468-1253(22)00317-x.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"486_CR19","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with Type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22(10):1999-2010.e8. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.006.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"17","key":"486_CR20","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385(17):1559\u201369. https:\/\/doi.org\/10.1056\/NEJMoa2029349.","journal-title":"N Engl J Med"},{"issue":"3","key":"486_CR21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VW Wong","year":"2023","unstructured":"Wong VW, Ekstedt M, Wong GL, Hagstr\u00f6m H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3):842\u201352. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.036.","journal-title":"J Hepatol"},{"issue":"11","key":"486_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14276","volume":"54","author":"BG Zhou","year":"2024","unstructured":"Zhou BG, Jiang X, She Q, Ding YB. Association of MASLD with the risk of extrahepatic cancers: a systematic review and meta-analysis of 18 cohort studies. Eur J Clin Invest. 2024;54(11):e14276. https:\/\/doi.org\/10.1111\/eci.14276.","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"486_CR23","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.cgh.2022.07.033","volume":"21","author":"P Le","year":"2023","unstructured":"Le P, Payne JY, Zhang L, Deshpande A, Rothberg MB, Alkhouri N, et al. Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies. Clin Gastroenterol Hepatol. 2023;21(5):1154\u201368. https:\/\/doi.org\/10.1016\/j.cgh.2022.07.033.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"486_CR24","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, Hagstr\u00f6m H, Nasr P, Schattenberg JM, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611-25.e12. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.043.","journal-title":"Gastroenterology"},{"issue":"5","key":"486_CR25","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557\u201365. https:\/\/doi.org\/10.1002\/hep.29085.","journal-title":"Hepatology"},{"key":"486_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2020.05.062","author":"PC M\u00fcller","year":"2020","unstructured":"M\u00fcller PC, Kabacam G, Vibert E, Germani G, Petrowsky H. Current status of liver transplantation in Europe. Int J Surg. 2020. https:\/\/doi.org\/10.1016\/j.ijsu.2020.05.062.","journal-title":"Int J Surg"},{"issue":"7","key":"486_CR27","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD. Metabolic dysfunction-associated steatotic liver disease. N Engl J Med. 2025;393(7):683\u201398. https:\/\/doi.org\/10.1056\/NEJMra2412865.","journal-title":"N Engl J Med"},{"issue":"2","key":"486_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jhep.2024.08.008","volume":"82","author":"YH Zhang","year":"2025","unstructured":"Zhang YH, Xie R, Dai CS, Gao HW, Zhou G, Qi TT, et al. Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids. J Hepatol. 2025;82(2):189\u2013202. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.008.","journal-title":"J Hepatol"},{"issue":"5","key":"486_CR29","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/jci23621","volume":"115","author":"KL Donnelly","year":"2005","unstructured":"Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343\u201351. https:\/\/doi.org\/10.1172\/jci23621.","journal-title":"J Clin Invest"},{"issue":"10","key":"486_CR30","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537\u201364. https:\/\/doi.org\/10.1016\/j.cell.2021.04.015.","journal-title":"Cell"},{"issue":"6","key":"486_CR31","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1172\/jci45887","volume":"121","author":"K Sun","year":"2011","unstructured":"Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest. 2011;121(6):2094\u2013101. https:\/\/doi.org\/10.1172\/jci45887.","journal-title":"J Clin Invest"},{"key":"486_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084156","author":"Y Sakurai","year":"2021","unstructured":"Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22084156.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"486_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","volume":"142","author":"K Cusi","year":"2012","unstructured":"Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711-25.e6. https:\/\/doi.org\/10.1053\/j.gastro.2012.02.003.","journal-title":"Gastroenterology"},{"key":"486_CR34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2111737119","author":"C Chen","year":"2022","unstructured":"Chen C, Gu L, Matye DJ, Clayton YD, Hasan MN, Wang Y, et al. Cullin neddylation inhibitor attenuates hyperglycemia by enhancing hepatic insulin signaling through insulin receptor substrate stabilization. Proc Natl Acad Sci U S A. 2022. https:\/\/doi.org\/10.1073\/pnas.2111737119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"486_CR35","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s00125-012-2644-8","volume":"55","author":"KD Copps","year":"2012","unstructured":"Copps KD, White MF. Regulation of insulin sensitivity by serine\/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia. 2012;55(10):2565\u201382. https:\/\/doi.org\/10.1007\/s00125-012-2644-8.","journal-title":"Diabetologia"},{"issue":"6","key":"486_CR36","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.cell.2010.02.034","volume":"140","author":"GS Hotamisligil","year":"2010","unstructured":"Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140(6):900\u201317. https:\/\/doi.org\/10.1016\/j.cell.2010.02.034.","journal-title":"Cell"},{"issue":"4","key":"486_CR37","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cell.2018.09.055","volume":"175","author":"A Koh","year":"2018","unstructured":"Koh A, Molinaro A, St\u00e5hlman M, Khan MT, Schmidt C, Manner\u00e5s-Holm L, et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell. 2018;175(4):947-61.e17. https:\/\/doi.org\/10.1016\/j.cell.2018.09.055.","journal-title":"Cell"},{"issue":"1","key":"486_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1097-2765(05)00010-9","volume":"6","author":"I Shimomura","year":"2000","unstructured":"Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob\/ob mice. Mol Cell. 2000;6(1):77\u201386.","journal-title":"Mol Cell"},{"issue":"1","key":"486_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15684-0","volume":"11","author":"KHM Roumans","year":"2020","unstructured":"Roumans KHM, Lindeboom L, Veeraiah P, Remie CME, Phielix E, Havekes B, et al. Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. Nat Commun. 2020;11(1):1891. https:\/\/doi.org\/10.1038\/s41467-020-15684-0.","journal-title":"Nat Commun"},{"issue":"4","key":"486_CR40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41573-021-00367-2","volume":"21","author":"B Batchuluun","year":"2022","unstructured":"Batchuluun B, Pinkosky SL, Steinberg GR. Lipogenesis inhibitors: therapeutic opportunities and challenges. Nat Rev Drug Discov. 2022;21(4):283\u2013305. https:\/\/doi.org\/10.1038\/s41573-021-00367-2.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"486_CR41","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/hep.30429","volume":"70","author":"RS Khan","year":"2019","unstructured":"Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019;70(2):711\u201324. https:\/\/doi.org\/10.1002\/hep.30429.","journal-title":"Hepatology"},{"issue":"2","key":"486_CR42","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","volume":"83","author":"GR Steinberg","year":"2025","unstructured":"Steinberg GR, Valvano CM, De Nardo W, Watt MJ. Integrative metabolism in MASLD and MASH: pathophysiology and emerging mechanisms. J Hepatol. 2025;83(2):584\u201395. https:\/\/doi.org\/10.1016\/j.jhep.2025.02.033.","journal-title":"J Hepatol"},{"issue":"6","key":"486_CR43","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.cmet.2011.11.004","volume":"14","author":"NE Sunny","year":"2011","unstructured":"Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011;14(6):804\u201310. https:\/\/doi.org\/10.1016\/j.cmet.2011.11.004.","journal-title":"Cell Metab"},{"issue":"4","key":"486_CR44","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1872-034X.2008.00464.x","volume":"39","author":"H Mitsuyoshi","year":"2009","unstructured":"Mitsuyoshi H, Yasui K, Harano Y, Endo M, Tsuji K, Minami M, et al. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res. 2009;39(4):366\u201373. https:\/\/doi.org\/10.1111\/j.1872-034X.2008.00464.x.","journal-title":"Hepatol Res"},{"issue":"5","key":"486_CR45","doi-asserted-by":"publisher","first-page":"G1281","DOI":"10.1152\/ajpgi.00074.2008","volume":"294","author":"D Greco","year":"2008","unstructured":"Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol. 2008;294(5):G1281\u20137. https:\/\/doi.org\/10.1152\/ajpgi.00074.2008.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"486_CR46","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.1478-3231.2010.02248.x","volume":"30","author":"LP Bechmann","year":"2010","unstructured":"Bechmann LP, Gieseler RK, Sowa JP, Kahraman A, Erhard J, Wedemeyer I, et al. Apoptosis is associated with CD36\/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int. 2010;30(6):850\u20139. https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02248.x.","journal-title":"Liver Int"},{"issue":"4","key":"486_CR47","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1210\/jc.2015-3476","volume":"101","author":"MK Poulsen","year":"2016","unstructured":"Poulsen MK, Nellemann B, St\u00f8dkilde-J\u00f8rgensen H, Pedersen SB, Gr\u00f8nb\u00e6k H, Nielsen S. Impaired insulin suppression of VLDL-triglyceride kinetics in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2016;101(4):1637\u201346. https:\/\/doi.org\/10.1210\/jc.2015-3476.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"486_CR48","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","volume":"21","author":"C Koliaki","year":"2015","unstructured":"Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015;21(5):739\u201346. https:\/\/doi.org\/10.1016\/j.cmet.2015.04.004.","journal-title":"Cell Metab"},{"issue":"3","key":"486_CR49","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.gastro.2018.06.083","volume":"155","author":"A Mansouri","year":"2018","unstructured":"Mansouri A, Gattolliat CH, Asselah T. Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology. 2018;155(3):629\u201347. https:\/\/doi.org\/10.1053\/j.gastro.2018.06.083.","journal-title":"Gastroenterology"},{"issue":"1","key":"486_CR50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","volume":"52","author":"AP Rolo","year":"2012","unstructured":"Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52(1):59\u201369. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2011.10.003.","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"486_CR51","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1152\/physrev.00058.2021","volume":"103","author":"JS Harrington","year":"2023","unstructured":"Harrington JS, Ryter SW, Plataki M, Price DR, Choi AMK. Mitochondria in health, disease, and aging. Physiol Rev. 2023;103(4):2349\u2013422. https:\/\/doi.org\/10.1152\/physrev.00058.2021.","journal-title":"Physiol Rev"},{"issue":"1","key":"486_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1416","volume":"10","author":"SJ Dixon","year":"2014","unstructured":"Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10(1):9\u201317. https:\/\/doi.org\/10.1038\/nchembio.1416.","journal-title":"Nat Chem Biol"},{"issue":"8","key":"486_CR53","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.immuni.2022.06.007","volume":"55","author":"H Xian","year":"2022","unstructured":"Xian H, Watari K, Sanchez-Lopez E, Offenberger J, Onyuru J, Sampath H, et al. Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling. Immunity. 2022;55(8):1370-85.e8. https:\/\/doi.org\/10.1016\/j.immuni.2022.06.007.","journal-title":"Immunity"},{"key":"486_CR54","doi-asserted-by":"publisher","first-page":"103393","DOI":"10.1016\/j.redox.2024.103393","volume":"77","author":"L Beucher","year":"2024","unstructured":"Beucher L, Gabillard-Lefort C, Baris OR, Mialet-Perez J. Monoamine oxidases: A missing link between mitochondria and inflammation in chronic diseases\u202f? Redox Biol. 2024;77:103393. https:\/\/doi.org\/10.1016\/j.redox.2024.103393.","journal-title":"Redox Biol"},{"issue":"7","key":"486_CR55","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.metabol.2010.10.003","volume":"60","author":"L Zhu","year":"2011","unstructured":"Zhu L, Baker SS, Liu W, Tao MH, Patel R, Nowak NJ, et al. Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis. Metabolism. 2011;60(7):1001\u201311. https:\/\/doi.org\/10.1016\/j.metabol.2010.10.003.","journal-title":"Metabolism"},{"issue":"11","key":"486_CR56","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.2337\/db07-0156","volume":"56","author":"J Westerbacka","year":"2007","unstructured":"Westerbacka J, Kolak M, Kiviluoto T, Arkkila P, Sir\u00e9n J, Hamsten A, et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte\/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes. 2007;56(11):2759\u201365. https:\/\/doi.org\/10.2337\/db07-0156.","journal-title":"Diabetes"},{"issue":"5","key":"486_CR57","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1097\/hep.0000000000000386","volume":"78","author":"H Tilg","year":"2023","unstructured":"Tilg H, Adolph TE, Tacke F. Therapeutic modulation of the liver immune microenvironment. Hepatology. 2023;78(5):1581\u2013601. https:\/\/doi.org\/10.1097\/hep.0000000000000386.","journal-title":"Hepatology"},{"issue":"1","key":"486_CR58","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","volume":"42","author":"PR Lawler","year":"2021","unstructured":"Lawler PR, Bhatt DL, Godoy LC, L\u00fcscher TF, Bonow RO, Verma S, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42(1):113\u201331. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa099.","journal-title":"Eur Heart J"},{"issue":"7203","key":"486_CR59","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436\u201344. https:\/\/doi.org\/10.1038\/nature07205.","journal-title":"Nature"},{"issue":"4","key":"486_CR60","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595.","journal-title":"Gut"},{"issue":"3","key":"486_CR61","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/hep.31250","volume":"72","author":"M Tardelli","year":"2020","unstructured":"Tardelli M, Bruschi FV, Trauner M. The Role of Metabolic Lipases in the Pathogenesis and Management of Liver Disease. Hepatology. 2020;72(3):1117\u201326. https:\/\/doi.org\/10.1002\/hep.31250.","journal-title":"Hepatology"},{"issue":"3","key":"486_CR62","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1053\/j.gastro.2006.05.054","volume":"131","author":"H Tilg","year":"2006","unstructured":"Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006;131(3):934\u201345. https:\/\/doi.org\/10.1053\/j.gastro.2006.05.054.","journal-title":"Gastroenterology"},{"issue":"3","key":"486_CR63","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nm.3084","volume":"19","author":"S Kiechl","year":"2013","unstructured":"Kiechl S, Wittmann J, Giaccari A, Knoflach M, Willeit P, Bozec A, et al. Blockade of receptor activator of nuclear factor-\u03baB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med. 2013;19(3):358\u201363. https:\/\/doi.org\/10.1038\/nm.3084.","journal-title":"Nat Med"},{"issue":"2","key":"486_CR64","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","volume":"20","author":"T Gong","year":"2020","unstructured":"Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20(2):95\u2013112. https:\/\/doi.org\/10.1038\/s41577-019-0215-7.","journal-title":"Nat Rev Immunol"},{"key":"486_CR65","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.omtn.2021.11.008","volume":"26","author":"J Wang","year":"2021","unstructured":"Wang J, Hu W, Shen Z, Liu T, Dai W, Shen B, et al. Dissecting the single-cell transcriptomeunderlying chronic liver injury. Mol Ther Nucleic Acids. 2021;26:1364\u201373. https:\/\/doi.org\/10.1016\/j.omtn.2021.11.008.","journal-title":"Mol Ther Nucleic Acids"},{"key":"486_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101231","volume":"95","author":"M Parola","year":"2024","unstructured":"Parola M, Pinzani M. Liver fibrosis in NAFLD\/NASH: from pathophysiology towards diagnostic and therapeutic strategies. Mol Aspects Med. 2024;95:101231. https:\/\/doi.org\/10.1016\/j.mam.2023.101231.","journal-title":"Mol Aspects Med"},{"issue":"4","key":"486_CR67","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","volume":"77","author":"M Peiseler","year":"2022","unstructured":"Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenw\u00e4lder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol. 2022;77(4):1136\u201360. https:\/\/doi.org\/10.1016\/j.jhep.2022.06.012.","journal-title":"J Hepatol"},{"issue":"10","key":"486_CR68","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol. 2023;20(10):633\u201346. https:\/\/doi.org\/10.1038\/s41575-023-00807-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"486_CR69","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/nm.4027","volume":"22","author":"C Lood","year":"2016","unstructured":"Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, Smith CK, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. 2016;22(2):146\u201353. https:\/\/doi.org\/10.1038\/nm.4027.","journal-title":"Nat Med"},{"issue":"11","key":"486_CR70","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1136\/gutjnl-2023-331447","volume":"73","author":"M Babuta","year":"2024","unstructured":"Babuta M, Morel C, de Carvalho Ribeiro M, Calenda C, Ortega-Ribera M, Thevkar Nagesh P, et al. Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcohol-induced acceleration of MASH fibrosis. Gut. 2024;73(11):1854\u201369. https:\/\/doi.org\/10.1136\/gutjnl-2023-331447.","journal-title":"Gut"},{"issue":"12","key":"486_CR71","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1111\/jth.13147","volume":"13","author":"H Heijnen","year":"2015","unstructured":"Heijnen H, van der Sluijs P. Platelet secretory behaviour: as diverse as the granules \u2026 or not? J Thromb Haemost. 2015;13(12):2141\u201351. https:\/\/doi.org\/10.1111\/jth.13147.","journal-title":"J Thromb Haemost"},{"key":"486_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01256","volume":"10","author":"F Taus","year":"2019","unstructured":"Taus F, Meneguzzi A, Castelli M, Minuz P. Platelet-derived extracellular vesicles as target of antiplatelet agents. What is the evidence? Front Pharmacol. 2019;10:1256. https:\/\/doi.org\/10.3389\/fphar.2019.01256.","journal-title":"Front Pharmacol"},{"issue":"9","key":"486_CR73","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.4049\/jimmunol.1001623","volume":"186","author":"GT Brown","year":"2011","unstructured":"Brown GT, McIntyre TM. Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1\u03b2-rich microparticles. J Immunol. 2011;186(9):5489\u201396. https:\/\/doi.org\/10.4049\/jimmunol.1001623.","journal-title":"J Immunol"},{"issue":"9","key":"486_CR74","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s41590-025-02255-y","volume":"26","author":"OP Martin","year":"2025","unstructured":"Martin OP, Wallace MS, Oetheimer C, Patel HB, Butler MD, Wong LP, et al. Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis. Nat Immunol. 2025;26(9):1596\u2013611. https:\/\/doi.org\/10.1038\/s41590-025-02255-y.","journal-title":"Nat Immunol"},{"key":"486_CR75","doi-asserted-by":"publisher","DOI":"10.1172\/jci175305","author":"D Aki","year":"2024","unstructured":"Aki D, Hayakawa T, Srirat T, Shichino S, Ito M, Saitoh SI, et al. The Nr4a family regulates intrahepatic Treg proliferation and liver fibrosis in MASLD models. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/jci175305.","journal-title":"J Clin Invest"},{"issue":"4","key":"486_CR76","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/hep.32428","volume":"76","author":"M Karl","year":"2022","unstructured":"Karl M, Hasselwander S, Zhou Y, Reifenberg G, Kim YO, Park KS, et al. Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease. Hepatology. 2022;76(4):1135\u201349. https:\/\/doi.org\/10.1002\/hep.32428.","journal-title":"Hepatology"},{"issue":"2","key":"486_CR77","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","volume":"17","author":"S Sutti","year":"2020","unstructured":"Sutti S, Albano E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 2020;17(2):81\u201392. https:\/\/doi.org\/10.1038\/s41575-019-0210-2.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"486_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3823","volume":"4","author":"I Mederacke","year":"2013","unstructured":"Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823. https:\/\/doi.org\/10.1038\/ncomms3823.","journal-title":"Nat Commun"},{"issue":"6","key":"486_CR79","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/s0168-8278(99)80327-4","volume":"31","author":"F Marra","year":"1999","unstructured":"Marra F. Hepatic stellate cells and the regulation of liver inflammation. J Hepatol. 1999;31(6):1120\u201330. https:\/\/doi.org\/10.1016\/s0168-8278(99)80327-4.","journal-title":"J Hepatol"},{"issue":"3","key":"486_CR80","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/jci30542","volume":"117","author":"JP Iredale","year":"2007","unstructured":"Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 2007;117(3):539\u201348. https:\/\/doi.org\/10.1172\/jci30542.","journal-title":"J Clin Invest"},{"issue":"7","key":"486_CR81","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397\u2013411. https:\/\/doi.org\/10.1038\/nrgastro.2017.38.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"715","key":"486_CR82","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade2966","volume":"15","author":"C Quinn","year":"2023","unstructured":"Quinn C, Rico MC, Merali C, Barrero CA, Perez-Leal O, Mischley V, et al. Secreted folate receptor \u03b3 drives fibrogenesis in metabolic dysfunction-associated steatohepatitis by amplifying TGF\u03b2 signaling in hepatic stellate cells. Sci Transl Med. 2023;15(715):eade2966. https:\/\/doi.org\/10.1126\/scitranslmed.ade2966.","journal-title":"Sci Transl Med"},{"issue":"3","key":"486_CR83","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/hep.0000000000000569","volume":"79","author":"F Wang","year":"2024","unstructured":"Wang F, Chen L, Kong D, Zhang X, Xia S, Liang B, et al. Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A\/HIF-1\u03b1 transcriptional complex. Hepatology. 2024;79(3):606\u201323. https:\/\/doi.org\/10.1097\/hep.0000000000000569.","journal-title":"Hepatology"},{"issue":"677","key":"486_CR84","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add3949","volume":"15","author":"S Wang","year":"2023","unstructured":"Wang S, Li K, Pickholz E, Dobie R, Matchett KP, Henderson NC, et al. An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis. Sci Transl Med. 2023;15(677):eadd3949. https:\/\/doi.org\/10.1126\/scitranslmed.add3949.","journal-title":"Sci Transl Med"},{"issue":"7","key":"486_CR85","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","volume":"158","author":"RF Schwabe","year":"2020","unstructured":"Schwabe RF, Tabas I, Pajvani UB. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology. 2020;158(7):1913\u201328. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.311.","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"486_CR86","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s12072-024-10667-5","volume":"18","author":"V Moretti","year":"2024","unstructured":"Moretti V, Romeo S, Valenti L. The contribution of genetics and epigenetics to MAFLD susceptibility. Hepatol Int. 2024;18(Suppl 2):848\u201360. https:\/\/doi.org\/10.1007\/s12072-024-10667-5.","journal-title":"Hepatol Int"},{"issue":"2","key":"486_CR87","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68(2):268\u201379. https:\/\/doi.org\/10.1016\/j.jhep.2017.09.003.","journal-title":"J Hepatol"},{"issue":"1","key":"486_CR88","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","volume":"61","author":"YL Liu","year":"2014","unstructured":"Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol. 2014;61(1):75\u201381. https:\/\/doi.org\/10.1016\/j.jhep.2014.02.030.","journal-title":"J Hepatol"},{"issue":"41","key":"486_CR89","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.3748\/wjg.v19.i41.6969","volume":"19","author":"P Dongiovanni","year":"2013","unstructured":"Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol. 2013;19(41):6969\u201378. https:\/\/doi.org\/10.3748\/wjg.v19.i41.6969.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"486_CR90","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.bbalip.2013.12.006","volume":"1841","author":"P Pingitore","year":"2014","unstructured":"Pingitore P, Pirazzi C, Mancina RM, Motta BM, Indiveri C, Pujia A, et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta. 2014;1841(4):574\u201380. https:\/\/doi.org\/10.1016\/j.bbalip.2013.12.006.","journal-title":"Biochim Biophys Acta"},{"issue":"15","key":"486_CR91","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1093\/hmg\/ddu121","volume":"23","author":"C Pirazzi","year":"2014","unstructured":"Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, Mancina RM, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet. 2014;23(15):4077\u201385. https:\/\/doi.org\/10.1093\/hmg\/ddu121.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"486_CR92","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybj\u00e6rg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46(4):352\u20136. https:\/\/doi.org\/10.1038\/ng.2901.","journal-title":"Nat Genet"},{"issue":"5","key":"486_CR93","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","volume":"150","author":"RM Mancina","year":"2016","unstructured":"Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology. 2016;150(5):1219-30.e6. https:\/\/doi.org\/10.1053\/j.gastro.2016.01.032.","journal-title":"Gastroenterology"},{"issue":"3","key":"486_CR94","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/hep.24806","volume":"55","author":"N Santoro","year":"2012","unstructured":"Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology. 2012;55(3):781\u20139. https:\/\/doi.org\/10.1002\/hep.24806.","journal-title":"Hepatology"},{"key":"486_CR95","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.mam.2016.11.008","volume":"54","author":"J Lee","year":"2017","unstructured":"Lee J, Kim Y, Friso S, Choi SW. Epigenetics in non-alcoholic fatty liver disease. Mol Aspects Med. 2017;54:78\u201388. https:\/\/doi.org\/10.1016\/j.mam.2016.11.008.","journal-title":"Mol Aspects Med"},{"issue":"6","key":"486_CR96","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/hep.23927","volume":"52","author":"S Sookoian","year":"2010","unstructured":"Sookoian S, Rosselli MS, Gemma C, Burgue\u00f1o AL, Fern\u00e1ndez Gianotti T, Casta\u00f1o GO, et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor \u03b3 coactivator 1\u03b1 promoter. Hepatology. 2010;52(6):1992\u20132000. https:\/\/doi.org\/10.1002\/hep.23927.","journal-title":"Hepatology"},{"issue":"4","key":"486_CR97","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cmet.2009.02.006","volume":"9","author":"A Purushotham","year":"2009","unstructured":"Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9(4):327\u201338. https:\/\/doi.org\/10.1016\/j.cmet.2009.02.006.","journal-title":"Cell Metab"},{"issue":"6 Pt B","key":"486_CR98","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.semcancer.2013.08.010","volume":"23","author":"Y Tian","year":"2013","unstructured":"Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol. 2013;23(6 Pt B):471\u201382. https:\/\/doi.org\/10.1016\/j.semcancer.2013.08.010.","journal-title":"Semin Cancer Biol"},{"issue":"15","key":"486_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412903","volume":"12","author":"F Zhang","year":"2025","unstructured":"Zhang F, Yue K, Sun S, Lu S, Jia G, Zha Y, et al. Targeting histone deacetylase 11 with a highly selective inhibitor for the treatment of MASLD. Adv Sci (Weinh). 2025;12(15):e2412903. https:\/\/doi.org\/10.1002\/advs.202412903.","journal-title":"Adv Sci (Weinh)"},{"key":"486_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101581","volume":"65","author":"MY Hochreuter","year":"2022","unstructured":"Hochreuter MY, Dall M, Treebak JT, Barres R. MicroRNAs in non-alcoholic fatty liver disease: progress and perspectives. Mol Metab. 2022;65:101581. https:\/\/doi.org\/10.1016\/j.molmet.2022.101581.","journal-title":"Mol Metab"},{"issue":"11","key":"486_CR101","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/s2468-1253(20)30252-1","volume":"5","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(11):970\u201385. https:\/\/doi.org\/10.1016\/s2468-1253(20)30252-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"486_CR102","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/liv.15682","volume":"43","author":"PM Rodrigues","year":"2023","unstructured":"Rodrigues PM, Afonso MB, Sim\u00e3o AL, Islam T, Gaspar MM, O\u2019Rourke CJ, et al. miR-21-5p promotes NASH-related hepatocarcinogenesis. Liver Int. 2023;43(10):2256\u201374. https:\/\/doi.org\/10.1111\/liv.15682.","journal-title":"Liver Int"},{"issue":"1","key":"486_CR103","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/jcma.0000000000000230","volume":"83","author":"Y Chien","year":"2020","unstructured":"Chien Y, Tsai PH, Lai YH, Lu KH, Liu CY, Lin HF, et al. CircularRNA as novel biomarkers in liver diseases. J Chin Med Assoc. 2020;83(1):15\u20137. https:\/\/doi.org\/10.1097\/jcma.0000000000000230.","journal-title":"J Chin Med Assoc"},{"key":"486_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/srep22640","volume":"6","author":"C Yan","year":"2016","unstructured":"Yan C, Chen J, Chen N. Long noncoding RNA MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability. Sci Rep. 2016;6:22640. https:\/\/doi.org\/10.1038\/srep22640.","journal-title":"Sci Rep"},{"issue":"Suppl","key":"486_CR105","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.3350\/cmh.2024.0811","volume":"31","author":"H Saeed","year":"2025","unstructured":"Saeed H, D\u00edaz LA, Gil-G\u00f3mez A, Burton J, Bajaj JS, Romero-Gomez M, et al. Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S94-s111. https:\/\/doi.org\/10.3350\/cmh.2024.0811.","journal-title":"Clin Mol Hepatol"},{"key":"486_CR106","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.mib.2018.06.003","volume":"44","author":"K Korpela","year":"2018","unstructured":"Korpela K, de Vos WM. Early life colonization of the human gut: microbes matter everywhere. Curr Opin Microbiol. 2018;44:70\u20138. https:\/\/doi.org\/10.1016\/j.mib.2018.06.003.","journal-title":"Curr Opin Microbiol"},{"issue":"1","key":"486_CR107","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/jgh.13058","volume":"31","author":"S Kapil","year":"2016","unstructured":"Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016;31(1):213\u201321. https:\/\/doi.org\/10.1111\/jgh.13058.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"486_CR108","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","volume":"63","author":"J Boursier","year":"2016","unstructured":"Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764\u201375. https:\/\/doi.org\/10.1002\/hep.28356.","journal-title":"Hepatology"},{"issue":"5","key":"486_CR109","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1053\/j.gastro.2020.07.005","volume":"159","author":"S Lang","year":"2020","unstructured":"Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, et al. Intestinal virome signature associated with severity of Nonalcoholic Fatty Liver Disease. Gastroenterology. 2020;159(5):1839\u201352. https:\/\/doi.org\/10.1053\/j.gastro.2020.07.005.","journal-title":"Gastroenterology"},{"issue":"1","key":"486_CR110","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cmet.2020.11.010","volume":"33","author":"SR Sharpton","year":"2021","unstructured":"Sharpton SR, Schnabl B, Knight R, Loomba R. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in Nonalcoholic Fatty Liver Disease. Cell Metab. 2021;33(1):21\u201332. https:\/\/doi.org\/10.1016\/j.cmet.2020.11.010.","journal-title":"Cell Metab"},{"issue":"5","key":"486_CR111","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","volume":"25","author":"R Loomba","year":"2017","unstructured":"Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017;25(5):1054-62.e5. https:\/\/doi.org\/10.1016\/j.cmet.2017.04.001.","journal-title":"Cell Metab"},{"issue":"648","key":"486_CR112","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abk0855","volume":"14","author":"H Leung","year":"2022","unstructured":"Leung H, Long X, Ni Y, Qian L, Nychas E, Siliceo SL, et al. Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci Transl Med. 2022;14(648):eabk0855. https:\/\/doi.org\/10.1126\/scitranslmed.abk0855.","journal-title":"Sci Transl Med"},{"key":"486_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.974872","volume":"13","author":"F Xie","year":"2022","unstructured":"Xie F, Xu HF, Zhang J, Liu XN, Kou BX, Cai MY, et al. Dysregulated hepatic lipid metabolism and gut microbiota associated with early-stage NAFLD in ASPP2-deficiency mice. Front Immunol. 2022;13:974872. https:\/\/doi.org\/10.3389\/fimmu.2022.974872.","journal-title":"Front Immunol"},{"key":"486_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042183","author":"H Yuan","year":"2024","unstructured":"Yuan H, Wu X, Wang X, Zhou JY, Park S. Microbial dysbiosis linked to metabolic dysfunction-associated fatty liver disease in Asians: Prevotella copri promotes lipopolysaccharide biosynthesis and network instability in the Prevotella enterotype. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25042183.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"486_CR115","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/hep.31056","volume":"72","author":"G Carpino","year":"2020","unstructured":"Carpino G, Del Ben M, Pastori D, Carnevale R, Baratta F, Overi D, et al. Increased liver localization of lipopolysaccharides in human and experimental NAFLD. Hepatology. 2020;72(2):470\u201385. https:\/\/doi.org\/10.1002\/hep.31056.","journal-title":"Hepatology"},{"key":"486_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2023.109434","volume":"121","author":"D Zhang","year":"2023","unstructured":"Zhang D, Wang H, Liu A, Wang S, Xu C, Lan K, et al. The chronic consumption of dietary fructose promotes the gut Clostridium species imbalance and bile acid alterations in developing Nonalcoholic Fatty Liver Disease. J Nutr Biochem. 2023;121:109434. https:\/\/doi.org\/10.1016\/j.jnutbio.2023.109434.","journal-title":"J Nutr Biochem"},{"issue":"1","key":"486_CR117","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s42255-024-01177-7","volume":"7","author":"X Zhang","year":"2025","unstructured":"Zhang X, Lau HC, Ha S, Liu C, Liang C, Lee HW, et al. Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis. Nat Metab. 2025;7(1):102\u201319. https:\/\/doi.org\/10.1038\/s42255-024-01177-7.","journal-title":"Nat Metab"},{"issue":"5","key":"486_CR118","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042.","journal-title":"Cell"},{"issue":"2","key":"486_CR119","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jhep.2020.04.001","volume":"73","author":"J Gautheron","year":"2020","unstructured":"Gautheron J, Gores GJ, Rodrigues CMP. Lytic cell death in metabolic liver disease. J Hepatol. 2020;73(2):394\u2013408. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.001.","journal-title":"J Hepatol"},{"issue":"2","key":"486_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11(2):88. https:\/\/doi.org\/10.1038\/s41419-020-2298-2.","journal-title":"Cell Death Dis"},{"issue":"1","key":"486_CR121","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ajpath.2019.09.011","volume":"190","author":"J Qi","year":"2020","unstructured":"Qi J, Kim JW, Zhou Z, Lim CW, Kim B. Ferroptosis affects the progression of Nonalcoholic Steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice. Am J Pathol. 2020;190(1):68\u201381. https:\/\/doi.org\/10.1016\/j.ajpath.2019.09.011.","journal-title":"Am J Pathol"},{"issue":"6","key":"486_CR122","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1111\/liv.14428","volume":"40","author":"X Li","year":"2020","unstructured":"Li X, Wang TX, Huang X, Li Y, Sun T, Zang S, et al. Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity. Liver Int. 2020;40(6):1378\u201394. https:\/\/doi.org\/10.1111\/liv.14428.","journal-title":"Liver Int"},{"issue":"5","key":"486_CR123","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41401-022-01010-5","volume":"44","author":"J Tong","year":"2023","unstructured":"Tong J, Lan XT, Zhang Z, Liu Y, Sun DY, Wang XJ, et al. Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis. Acta Pharmacol Sin. 2023;44(5):1014\u201328. https:\/\/doi.org\/10.1038\/s41401-022-01010-5.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"486_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2023.159287","volume":"1868","author":"H Liu","year":"2023","unstructured":"Liu H, Yan J, Guan F, Jin Z, Xie J, Wang C, et al. Zeaxanthin prevents ferroptosis by promoting mitochondrial function and inhibiting the p53 pathway in free fatty acid-induced HepG2 cells. Biochim Biophys Acta Mol Cell Biol Lipids. 2023;1868(4):159287. https:\/\/doi.org\/10.1016\/j.bbalip.2023.159287.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"486_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174351","volume":"908","author":"Z Zhu","year":"2021","unstructured":"Zhu Z, Zhang Y, Huang X, Can L, Zhao X, Wang Y, et al. Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4. Eur J Pharmacol. 2021;908:174351. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174351.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"486_CR126","doi-asserted-by":"publisher","DOI":"10.1007\/s10142-025-01579-0","volume":"25","author":"A El-Sehrawy","year":"2025","unstructured":"El-Sehrawy A, Rashid TA, Ullah MI, Uthirapathy S, Ganesan S, Singh A, et al. Cutting edge: ferroptosis in metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis and therapy. Funct Integr Genomics. 2025;25(1):71. https:\/\/doi.org\/10.1007\/s10142-025-01579-0.","journal-title":"Funct Integr Genomics"},{"issue":"1","key":"486_CR127","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/er.2016-1103","volume":"38","author":"RA Sinha","year":"2017","unstructured":"Sinha RA, Singh BK, Yen PM. Reciprocal crosstalk between autophagic and endocrine signaling in metabolic homeostasis. Endocr Rev. 2017;38(1):69\u2013102. https:\/\/doi.org\/10.1210\/er.2016-1103.","journal-title":"Endocr Rev"},{"issue":"3","key":"486_CR128","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.livres.2018.09.004","volume":"2","author":"B Khambu","year":"2018","unstructured":"Khambu B, Yan S, Huda N, Liu G, Yin XM. Autophagy in non-alcoholic fatty liver disease and alcoholic liver disease. Liver Res. 2018;2(3):112\u20139. https:\/\/doi.org\/10.1016\/j.livres.2018.09.004.","journal-title":"Liver Res"},{"issue":"1","key":"486_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s44324-024-00022-5","volume":"2","author":"S Raza","year":"2024","unstructured":"Raza S, Rajak S, Yen PM, Sinha RA. Autophagy and hepatic lipid metabolism: mechanistic insight and therapeutic potential for MASLD. NPJ Metab Health Dis. 2024;2(1):19. https:\/\/doi.org\/10.1038\/s44324-024-00022-5.","journal-title":"NPJ Metab Health Dis"},{"issue":"2","key":"486_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04593-3","volume":"13","author":"S Zhang","year":"2022","unstructured":"Zhang S, Peng X, Yang S, Li X, Huang M, Wei S, et al. The regulation, function, and role of lipophagy, a form of selective autophagy, in metabolic disorders. Cell Death Dis. 2022;13(2):132. https:\/\/doi.org\/10.1038\/s41419-022-04593-3.","journal-title":"Cell Death Dis"},{"issue":"1","key":"486_CR131","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41467-019-08829-3","volume":"10","author":"T Saito","year":"2019","unstructured":"Saito T, Kuma A, Sugiura Y, Ichimura Y, Obata M, Kitamura H, et al. Autophagy regulates lipid metabolism through selective turnover of NCoR1. Nat Commun. 2019;10(1):1567. https:\/\/doi.org\/10.1038\/s41467-019-08829-3.","journal-title":"Nat Commun"},{"issue":"1","key":"486_CR132","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41467-024-44978-w","volume":"15","author":"Z Yuan","year":"2024","unstructured":"Yuan Z, Cai K, Li J, Chen R, Zhang F, Tan X, et al. ATG14 targets lipid droplets and acts as an autophagic receptor for syntaxin18-regulated lipid droplet turnover. Nat Commun. 2024;15(1):631. https:\/\/doi.org\/10.1038\/s41467-024-44978-w.","journal-title":"Nat Commun"},{"key":"486_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156487","volume":"176","author":"B Chen","year":"2026","unstructured":"Chen B, Ma YY, Zhang MQ, Zhang R, Li SF, Wu LZ, et al. Suppression of hepatosteatosis by isarubrolone C through AMPK-dependent regulation of lipophagy and lipid metabolism. Metabolism. 2026;176:156487. https:\/\/doi.org\/10.1016\/j.metabol.2025.156487.","journal-title":"Metabolism"},{"issue":"5","key":"486_CR134","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/hep.22187","volume":"47","author":"JS Kim","year":"2008","unstructured":"Kim JS, Nitta T, Mohuczy D, O\u2019Malley KA, Moldawer LL, Dunn WA Jr, et al. Impaired autophagy: A mechanism of mitochondrial dysfunction in anoxic rat hepatocytes. Hepatology. 2008;47(5):1725\u201336. https:\/\/doi.org\/10.1002\/hep.22187.","journal-title":"Hepatology"},{"issue":"6","key":"486_CR135","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/hep.28820","volume":"64","author":"S Tanaka","year":"2016","unstructured":"Tanaka S, Hikita H, Tatsumi T, Sakamori R, Nozaki Y, Sakane S, et al. Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice. Hepatology. 2016;64(6):1994\u20132014. https:\/\/doi.org\/10.1002\/hep.28820.","journal-title":"Hepatology"},{"issue":"5","key":"486_CR136","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jhep.2022.06.033","volume":"77","author":"M Tripathi","year":"2022","unstructured":"Tripathi M, Singh BK, Zhou J, Tikno K, Widjaja A, Sandireddy R, et al. Vitamin B(12) and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation. J Hepatol. 2022;77(5):1246\u201355. https:\/\/doi.org\/10.1016\/j.jhep.2022.06.033.","journal-title":"J Hepatol"},{"issue":"5","key":"486_CR137","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.aohep.2020.06.001","volume":"19","author":"H Ding","year":"2020","unstructured":"Ding H, Ge G, Tseng Y, Ma Y, Zhang J, Liu J. Hepatic autophagy fluctuates during the development of non-alcoholic fatty liver disease. Ann Hepatol. 2020;19(5):516\u201322. https:\/\/doi.org\/10.1016\/j.aohep.2020.06.001.","journal-title":"Ann Hepatol"},{"issue":"5","key":"486_CR138","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jhep.2013.01.011","volume":"58","author":"CW Lin","year":"2013","unstructured":"Lin CW, Zhang H, Li M, Xiong X, Chen X, Chen X, et al. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. J Hepatol. 2013;58(5):993\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2013.01.011.","journal-title":"J Hepatol"},{"issue":"4","key":"486_CR139","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3803\/EnM.2024.2223","volume":"40","author":"SW Lee","year":"2025","unstructured":"Lee SW, Park H, Lee M, Lee H, Kang ES. Sodium-Glucose Cotransporter-2 Inhibitor Enhances Hepatic Gluconeogenesis and Reduces Lipid Accumulation via AMPK-SIRT1 Activation and Autophagy Induction. Endocrinol Metab (Seoul). 2025;40(4):583\u201397. https:\/\/doi.org\/10.3803\/EnM.2024.2223.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"486_CR140","doi-asserted-by":"publisher","DOI":"10.1172\/jci158450","author":"L Zhang","year":"2022","unstructured":"Zhang L, Pitcher LE, Yousefzadeh MJ, Niedernhofer LJ, Robbins PD, Zhu Y. Cellular senescence: a key therapeutic target in aging and diseases. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/jci158450.","journal-title":"J Clin Invest"},{"issue":"39","key":"486_CR141","doi-asserted-by":"publisher","first-page":"14185","DOI":"10.3748\/wjg.v20.i39.14185","volume":"20","author":"M Bertolotti","year":"2014","unstructured":"Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, et al. Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol. 2014;20(39):14185\u2013204. https:\/\/doi.org\/10.3748\/wjg.v20.i39.14185.","journal-title":"World J Gastroenterol"},{"key":"486_CR142","doi-asserted-by":"publisher","DOI":"10.1172\/jci180310","author":"JH Jun","year":"2024","unstructured":"Jun JH, Du K, Dutta RK, Maeso-Diaz R, Oh SH, Wang L, et al. The senescence-associated secretome of Hedgehog-deficient hepatocytes drives MASLD progression. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/jci180310.","journal-title":"J Clin Invest"},{"issue":"4","key":"486_CR143","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jhep.2016.05.030","volume":"65","author":"AD Aravinthan","year":"2016","unstructured":"Aravinthan AD, Alexander GJM. Senescence in chronic liver disease: is the future in aging? J Hepatol. 2016;65(4):825\u201334. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.030.","journal-title":"J Hepatol"},{"key":"486_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15691","volume":"8","author":"M Ogrodnik","year":"2017","unstructured":"Ogrodnik M, Miwa S, Tchkonia T, Tiniakos D, Wilson CL, Lahat A, et al. Cellular senescence drives age-dependent hepatic steatosis. Nat Commun. 2017;8:15691. https:\/\/doi.org\/10.1038\/ncomms15691.","journal-title":"Nat Commun"},{"key":"486_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104481","volume":"90","author":"A Nambiar","year":"2023","unstructured":"Nambiar A, Kellogg D 3rd, Justice J, Goros M, Gelfond J, Pascual R, et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. EBioMedicine. 2023;90:104481. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104481.","journal-title":"EBioMedicine"},{"issue":"3","key":"486_CR146","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"European Association for the Study of the Liver","year":"2021","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659\u201389. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025.","journal-title":"J Hepatol."},{"issue":"1","key":"486_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101133","volume":"29","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29(1):101133. https:\/\/doi.org\/10.1016\/j.aohep.2023.101133.","journal-title":"Ann Hepatol"},{"issue":"4","key":"486_CR148","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/hep.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347. https:\/\/doi.org\/10.1097\/hep.0000000000000004.","journal-title":"Hepatology"},{"issue":"5","key":"486_CR149","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264-81.e4. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036.","journal-title":"Gastroenterology"},{"issue":"4","key":"486_CR150","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/cld.740","volume":"13","author":"D Berger","year":"2019","unstructured":"Berger D, Desai V, Janardhan S. Con: liver biopsy remains the gold standard to evaluate fibrosis in patients with nonalcoholic fatty liver disease. Clin Liver Dis. 2019;13(4):114\u20136. https:\/\/doi.org\/10.1002\/cld.740.","journal-title":"Clin Liver Dis"},{"issue":"6","key":"486_CR151","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313\u201321. https:\/\/doi.org\/10.1002\/hep.20701.","journal-title":"Hepatology"},{"issue":"5","key":"486_CR152","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/hep.25889","volume":"56","author":"P Bedossa","year":"2012","unstructured":"Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56(5):1751\u20139. https:\/\/doi.org\/10.1002\/hep.25889.","journal-title":"Hepatology"},{"issue":"3","key":"486_CR153","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/hep.24127","volume":"53","author":"EM Brunt","year":"2011","unstructured":"Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810\u201320. https:\/\/doi.org\/10.1002\/hep.24127.","journal-title":"Hepatology"},{"issue":"27","key":"486_CR154","doi-asserted-by":"publisher","first-page":"9026","DOI":"10.3748\/wjg.v20.i27.9026","volume":"20","author":"IL Nalbantoglu","year":"2014","unstructured":"Nalbantoglu IL, Brunt EM. Role of liver biopsy in Nonalcoholic Fatty Liver Disease. World J Gastroenterol. 2014;20(27):9026\u201337. https:\/\/doi.org\/10.3748\/wjg.v20.i27.9026.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"486_CR155","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(6):1717\u201330. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.042.","journal-title":"Gastroenterology"},{"key":"486_CR156","doi-asserted-by":"publisher","unstructured":"Romero-G\u00f3mez M, Escalada J, Noguerol M, P\u00e9rez A, Carretero J, Crespo J, et al. Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis. Gastroenterol Hepatol. 2026:502639. https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502639.","DOI":"10.1016\/j.gastrohep.2025.502639"},{"issue":"2","key":"486_CR157","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","volume":"78","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Foucquier J, Younossi ZM, Harrison SA, Newsome PN, Chan WK, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol. 2023;78(2):247\u201359. https:\/\/doi.org\/10.1016\/j.jhep.2022.10.034.","journal-title":"J Hepatol"},{"issue":"4","key":"486_CR158","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/s2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with Nonalcoholic Steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362\u201373. https:\/\/doi.org\/10.1016\/s2468-1253(19)30383-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"486_CR159","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1002\/hep.28394","volume":"63","author":"C Cassinotto","year":"2016","unstructured":"Cassinotto C, Boursier J, de L\u00e9dinghen V, Lebigot J, Lapuyade B, Cales P, et al. Liver stiffness in Nonalcoholic Fatty Liver Disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology. 2016;63(6):1817\u201327. https:\/\/doi.org\/10.1002\/hep.28394.","journal-title":"Hepatology"},{"issue":"4","key":"486_CR160","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","volume":"75","author":"EA Selvaraj","year":"2021","unstructured":"Selvaraj EA, M\u00f3zes FE, Jayaswal ANA, Zafarmand MH, Vali Y, Lee JA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2021;75(4):770\u201385. https:\/\/doi.org\/10.1016\/j.jhep.2021.04.044.","journal-title":"J Hepatol"},{"issue":"3","key":"486_CR161","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","volume":"152","author":"CC Park","year":"2017","unstructured":"Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, et al. Magnetic Resonance Elastography vs Transient Elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven Nonalcoholic Fatty Liver Disease. Gastroenterology. 2017;152(3):598-607.e2. https:\/\/doi.org\/10.1053\/j.gastro.2016.10.026.","journal-title":"Gastroenterology"},{"issue":"2","key":"486_CR162","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1053\/j.gastro.2018.04.014","volume":"155","author":"V Ajmera","year":"2018","unstructured":"Ajmera V, Park CC, Caussy C, Singh S, Hernandez C, Bettencourt R, et al. Magnetic Resonance Imaging proton density fat fraction associates with progression of fibrosis in patients with Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018;155(2):307-10.e2. https:\/\/doi.org\/10.1053\/j.gastro.2018.04.014.","journal-title":"Gastroenterology"},{"issue":"5","key":"486_CR163","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1053\/j.gastro.2018.07.018","volume":"155","author":"B Wildman-Tobriner","year":"2018","unstructured":"Wildman-Tobriner B, Middleton MM, Moylan CA, Rossi S, Flores O, Chang ZA, et al. Association between Magnetic Resonance Imaging-proton density fat fraction and liver histology features in patients with Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis. Gastroenterology. 2018;155(5):1428-35.e2. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.018.","journal-title":"Gastroenterology"},{"issue":"3","key":"486_CR164","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jhep.2005.10.019","volume":"44","author":"J Parkes","year":"2006","unstructured":"Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic Hepatitis C. J Hepatol. 2006;44(3):462\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2005.10.019.","journal-title":"J Hepatol"},{"issue":"7","key":"486_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100765","volume":"5","author":"K Saarinen","year":"2023","unstructured":"Saarinen K, F\u00e4rkkil\u00e4 M, Jula A, Erlund I, Vihervaara T, Lundqvist A, et al. Enhanced liver Fibrosis\u00ae test predicts liver-related outcomes in the general population. JHEP Rep. 2023;5(7):100765. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100765.","journal-title":"JHEP Rep"},{"issue":"2","key":"486_CR166","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","volume":"79","author":"M Kjaergaard","year":"2023","unstructured":"Kjaergaard M, Lindvig KP, Thorhauge KH, Andersen P, Hansen JK, Kastrup N, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79(2):277\u201386. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.002.","journal-title":"J Hepatol"},{"issue":"4","key":"486_CR167","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/hep.23050","volume":"50","author":"AE Feldstein","year":"2009","unstructured":"Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50(4):1072\u20138. https:\/\/doi.org\/10.1002\/hep.23050.","journal-title":"Hepatology"},{"issue":"8","key":"486_CR168","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.clinthera.2025.05.006","volume":"47","author":"AY Zakaria","year":"2025","unstructured":"Zakaria AY, Badawi R, Osama H, Abdelrahman MA, El-Kalaawy AM. New approach combination-dosed therapy for nonalcoholic steatohepatitis versus vitamin E: a randomized controlled trial. Clin Ther. 2025;47(8):e19\u201330. https:\/\/doi.org\/10.1016\/j.clinthera.2025.05.006.","journal-title":"Clin Ther"},{"key":"486_CR169","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14176148","author":"K Iwaszko-Sochal","year":"2025","unstructured":"Iwaszko-Sochal K, Kasztelan-Szczerbi\u0144ska B, Cicho\u017c-Lach H. Is there a diagnostic miracle on the horizon? Emerging biomarkers in MASLD. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14176148.","journal-title":"J Clin Med"},{"issue":"6","key":"486_CR170","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/med.0000000000000935","volume":"32","author":"S Das","year":"2025","unstructured":"Das S, Agarwal K, Kapoor N, Lakhani OJ, Das Gupta A. Emerging concepts in the diagnosis and management of metabolically associated steatotic liver disease. Curr Opin Endocrinol Diabetes Obes. 2025;32(6):269\u201378. https:\/\/doi.org\/10.1097\/med.0000000000000935.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"486_CR171","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15182346","author":"D Raptis","year":"2025","unstructured":"Raptis D, Kolli ST, Agarwal S, Komminni PK, Bhattarai P, Hablani P, et al. Extracellular RNAs in liquid biopsy: applications in MASLD and MASH diagnosis and monitoring. Diagnostics Basel. 2025. https:\/\/doi.org\/10.3390\/diagnostics15182346.","journal-title":"Diagnostics Basel"},{"key":"486_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156028","volume":"161","author":"XF Zeng","year":"2024","unstructured":"Zeng XF, Varady KA, Wang XD, Targher G, Byrne CD, Tayyem R, et al. The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus. Metabolism. 2024;161:156028. https:\/\/doi.org\/10.1016\/j.metabol.2024.156028.","journal-title":"Metabolism"},{"key":"486_CR173","doi-asserted-by":"publisher","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","DOI":"10.1016\/j.jhep.2024.04.031"},{"issue":"6","key":"486_CR174","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/s41366-021-00788-4","volume":"45","author":"CL Haase","year":"2021","unstructured":"Haase CL, Lopes S, Olsen AH, Satylganova A, Schnecke V, McEwan P. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database. Int J Obes (Lond). 2021;45(6):1249\u201358. https:\/\/doi.org\/10.1038\/s41366-021-00788-4.","journal-title":"Int J Obes (Lond)"},{"key":"486_CR175","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001417","author":"H Liu","year":"2025","unstructured":"Liu H, Lefere S, Guillot A, Zheng MH, Tacke F. Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms. Hepatology. 2025. https:\/\/doi.org\/10.1097\/hep.0000000000001417.","journal-title":"Hepatology"},{"issue":"1","key":"486_CR176","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3350\/cmh.2024.0564","volume":"31","author":"NA Rouillard","year":"2025","unstructured":"Rouillard NA, Barnett SD, Zhang X, Kam L, Manikat R, Cheung R, et al. Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis. Clin Mol Hepatol. 2025;31(1):227\u201339. https:\/\/doi.org\/10.3350\/cmh.2024.0564.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"486_CR177","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/mcg.0000000000002140","volume":"59","author":"BP Lam","year":"2025","unstructured":"Lam BP, Bartholomew J, Bau S, Gilles H, Keller A, Moore A, et al. Focused recommendations for the management of metabolic dysfunction-associated steatohepatitis (MASH) by advanced practice providers in the United States. J Clin Gastroenterol. 2025;59(4):298\u2013309. https:\/\/doi.org\/10.1097\/mcg.0000000000002140.","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"486_CR178","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/14656566.2025.2478917","volume":"26","author":"S Bhushan","year":"2025","unstructured":"Bhushan S, Sohal A, Noureddin M, Kowdley KV. Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis. Expert Opin Pharmacother. 2025;26(6):663\u201375. https:\/\/doi.org\/10.1080\/14656566.2025.2478917.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"486_CR179","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"issue":"11\u201312","key":"486_CR180","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/apt.70382","volume":"62","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Rinella M, Taub R, Labriola D, Camacho RC, Alkhouri N, et al. Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and\/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. Aliment Pharmacol Ther. 2025;62(11\u201312):1089\u201399. https:\/\/doi.org\/10.1111\/apt.70382.","journal-title":"Aliment Pharmacol Ther"},{"issue":"18","key":"486_CR181","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675\u201385. https:\/\/doi.org\/10.1056\/NEJMoa0907929.","journal-title":"N Engl J Med"},{"issue":"8","key":"486_CR182","doi-asserted-by":"publisher","DOI":"10.2903\/j.efsa.2024.8953","volume":"22","author":"D Turck","year":"2024","unstructured":"Turck D, Bohn T, Castenmiller J, de Henauw S, Hirsch-Ernst KI, Knutsen HK, et al. Scientific opinion on the tolerable upper intake level for vitamin E. Efsa j. 2024;22(8):e8953. https:\/\/doi.org\/10.2903\/j.efsa.2024.8953.","journal-title":"Efsa j"},{"issue":"14","key":"486_CR183","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1001\/jama.2011.1437","volume":"306","author":"EA Klein","year":"2011","unstructured":"Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549\u201356. https:\/\/doi.org\/10.1001\/jama.2011.1437.","journal-title":"JAMA"},{"issue":"1","key":"486_CR184","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11030-025-11195-6","volume":"30","author":"A Saran","year":"2026","unstructured":"Saran A, Raisinghani R, Paliwal S, Sharma S. GLP-1R agonists: recent advances, current gaps, and future challenges. Mol Divers. 2026;30(1):101\u201312. https:\/\/doi.org\/10.1007\/s11030-025-11195-6.","journal-title":"Mol Divers"},{"issue":"9","key":"486_CR185","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1111\/jgh.17037","volume":"40","author":"D Ezhilarasan","year":"2025","unstructured":"Ezhilarasan D. Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key? J Gastroenterol Hepatol. 2025;40(9):2163\u201375. https:\/\/doi.org\/10.1111\/jgh.17037.","journal-title":"J Gastroenterol Hepatol"},{"key":"486_CR186","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.984041","volume":"13","author":"A Tsankof","year":"2022","unstructured":"Tsankof A, Neokosmidis G, Koureta E, Veneti S, Cholongitas E, Tziomalos K. Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease? Front Endocrinol (Lausanne). 2022;13:984041. https:\/\/doi.org\/10.3389\/fendo.2022.984041.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"486_CR187","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/dc18-1569","volume":"42","author":"A Latva-Rasku","year":"2019","unstructured":"Latva-Rasku A, Honka MJ, Kullberg J, Mononen N, Lehtim\u00e4ki T, Saltevo J, et al. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients. Diabetes Care. 2019;42(5):931\u20137. https:\/\/doi.org\/10.2337\/dc18-1569.","journal-title":"Diabetes Care"},{"key":"486_CR188","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-09464-3","author":"W Zhang","year":"2025","unstructured":"Zhang W, Hu H. The Emerging Therapeutic Promise of SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease. Dig Dis Sci. 2025. https:\/\/doi.org\/10.1007\/s10620-025-09464-3.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"486_CR189","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s13300-022-01239-7","volume":"13","author":"T Miyake","year":"2022","unstructured":"Miyake T, Yoshida O, Matsuura B, Furukawa S, Hirooka M, Abe M, et al. Additional effect of Luseogliflozin on Semaglutide in nonalcoholic steatohepatitis complicated by type 2 diabetes mellitus: an open-label, randomized, parallel-group study. Diabetes Ther. 2022;13(5):1083\u201396. https:\/\/doi.org\/10.1007\/s13300-022-01239-7.","journal-title":"Diabetes Ther"},{"issue":"1","key":"486_CR190","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-025-01298-8","volume":"27","author":"MS Safarova","year":"2025","unstructured":"Safarova MS, Weintraub S, Sadaniantz K, Kovell L, Warden BA, Garshick MS, et al. Statin use in special populations for the prevention of cardiovascular disease in adults. Curr Atheroscler Rep. 2025;27(1):54. https:\/\/doi.org\/10.1007\/s11883-025-01298-8.","journal-title":"Curr Atheroscler Rep"},{"key":"486_CR191","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000980","author":"RS Rahimi","year":"2026","unstructured":"Rahimi RS, Mena E, Lucas KJ, McRae MP, Kittelson J, Imperial JC, et al. HMG-CoA reductase inhibitors (statins) may preserve hepatic function and reduce portal-systemic shunting in compensated advanced chronic liver disease: results from the SHUNT-V study. Clin Transl Gastroenterol. 2026. https:\/\/doi.org\/10.14309\/ctg.0000000000000980.","journal-title":"Clin Transl Gastroenterol"},{"key":"486_CR192","doi-asserted-by":"publisher","DOI":"10.2174\/0118715206377993251115050803","author":"F Zarei","year":"2026","unstructured":"Zarei F, Salimi Z, Zeinivand M, Zamani N, Bahrani R. An overview of the antioxidant, anti-inflammatory, and anticancer effects of statins. Anticancer Agents Med Chem. 2026. https:\/\/doi.org\/10.2174\/0118715206377993251115050803.","journal-title":"Anticancer Agents Med Chem"},{"issue":"17","key":"486_CR193","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, et al. A randomized, controlled trial of the Pan-PPAR agonist Lanifibranor in NASH. N Engl J Med. 2021;385(17):1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2036205.","journal-title":"N Engl J Med"},{"issue":"4","key":"486_CR194","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/hep.31843","volume":"74","author":"S Gawrieh","year":"2021","unstructured":"Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, et al. Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial. Hepatology. 2021;74(4):1809\u201324. https:\/\/doi.org\/10.1002\/hep.31843.","journal-title":"Hepatology"},{"issue":"1","key":"486_CR195","doi-asserted-by":"publisher","first-page":"40","DOI":"10.14218\/jcth.2020.00055","volume":"9","author":"M Sharma","year":"2021","unstructured":"Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP. Drugs for non-alcoholic steatohepatitis (NASH): quest for the holy grail. J Clin Transl Hepatol. 2021;9(1):40\u201350. https:\/\/doi.org\/10.14218\/jcth.2020.00055.","journal-title":"J Clin Transl Hepatol"},{"issue":"5","key":"486_CR196","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","volume":"78","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Thang C, Bolze S, Dewitt S, Hallakou-Bozec S, Dubourg J, et al. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1). J Hepatol. 2023;78(5):914\u201325. https:\/\/doi.org\/10.1016\/j.jhep.2023.02.004.","journal-title":"J Hepatol"},{"issue":"24","key":"486_CR197","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","volume":"392","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Rinella ME, Chalasani NP, Neff GW, Lucas KJ, Rodriguez ME, et al. Efruxifermin in compensated liver cirrhosis caused by MASH. N Engl J Med. 2025;392(24):2413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2502242.","journal-title":"N Engl J Med"},{"issue":"11","key":"486_CR198","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, controlled trial of the FGF21 analogue Pegozafermin in NASH. N Engl J Med. 2023;389(11):998\u20131008. https:\/\/doi.org\/10.1056\/NEJMoa2304286.","journal-title":"N Engl J Med"},{"issue":"9","key":"486_CR199","doi-asserted-by":"publisher","first-page":"802","DOI":"10.14218\/jcth.2024.00123","volume":"12","author":"Y Hu","year":"2024","unstructured":"Hu Y, Sun C, Chen Y, Liu YD, Fan JG. Pipeline of new drug treatment for non-alcoholic fatty liver disease\/metabolic dysfunction-associated steatotic liver disease. J Clin Transl Hepatol. 2024;12(9):802\u201314. https:\/\/doi.org\/10.14218\/jcth.2024.00123.","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"486_CR200","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","volume":"160","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP, et al. Efficacy and safety of Aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology. 2021;160(1):219-31.e1. https:\/\/doi.org\/10.1053\/j.gastro.2020.08.004.","journal-title":"Gastroenterology"},{"issue":"5","key":"486_CR201","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","volume":"158","author":"N Chalasani","year":"2020","unstructured":"Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, et al. Effects of Belapectin, an inhibitor of Galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020;158(5):1334-45.e5. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.296.","journal-title":"Gastroenterology"},{"issue":"7","key":"486_CR202","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.medj.2021.04.007","volume":"2","author":"DJ Kazierad","year":"2021","unstructured":"Kazierad DJ, Chidsey K, Somayaji VR, Bergman AJ, Birnbaum MJ, Calle RA. Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: a randomized phase 2 trial. Med. 2021;2(7):800-13.e3. https:\/\/doi.org\/10.1016\/j.medj.2021.04.007.","journal-title":"Med"},{"issue":"2","key":"486_CR203","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Lopez P, Lawitz EJ, Lucas KJ, Loeffler J, Kim W, et al. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial. Nat Med. 2023;29(2):392\u2013400. https:\/\/doi.org\/10.1038\/s41591-022-02200-8.","journal-title":"Nat Med"},{"issue":"10215","key":"486_CR204","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/s0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184\u201396. https:\/\/doi.org\/10.1016\/s0140-6736(19)33041-7.","journal-title":"Lancet"},{"issue":"3","key":"486_CR205","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","volume":"76","author":"V Ratziu","year":"2022","unstructured":"Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, et al. EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022;76(3):506\u201317. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.018.","journal-title":"J Hepatol"},{"issue":"2","key":"486_CR206","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/hep.29514","volume":"67","author":"R Loomba","year":"2018","unstructured":"Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, et al. The ASK1 inhibitor Selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. 2018;67(2):549\u201359. https:\/\/doi.org\/10.1002\/hep.29514.","journal-title":"Hepatology"},{"issue":"1","key":"486_CR207","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","volume":"73","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26\u201339. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.027.","journal-title":"J Hepatol"},{"issue":"4","key":"486_CR208","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hep.29544","volume":"67","author":"O Krenkel","year":"2018","unstructured":"Krenkel O, Puengel T, Govaere O, Abdallah AT, Mossanen JC, Kohlhepp M, et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology. 2018;67(4):1270\u201383. https:\/\/doi.org\/10.1002\/hep.29544.","journal-title":"Hepatology"},{"issue":"3","key":"486_CR209","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/13543784.2018.1442436","volume":"27","author":"F Tacke","year":"2018","unstructured":"Tacke F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opin Investig Drugs. 2018;27(3):301\u201311. https:\/\/doi.org\/10.1080\/13543784.2018.1442436.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"486_CR210","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/meg.0000000000000348","volume":"27","author":"V Gangarapu","year":"2015","unstructured":"Gangarapu V, Ince AT, Baysal B, Kayar Y, K\u0131l\u0131\u00e7 U, G\u00f6k \u00d6, et al. Efficacy of Rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27(7):840\u20135. https:\/\/doi.org\/10.1097\/meg.0000000000000348.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"486_CR211","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/meg.0000000000001232","volume":"30","author":"A Abdel-Razik","year":"2018","unstructured":"Abdel-Razik A, Mousa N, Shabana W, Refaey M, Elzehery R, Elhelaly R, et al. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot. Eur J Gastroenterol Hepatol. 2018;30(10):1237\u201346. https:\/\/doi.org\/10.1097\/meg.0000000000001232.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"Suppl","key":"486_CR212","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.3350\/cmh.2024.0438","volume":"31","author":"A Caddeo","year":"2025","unstructured":"Caddeo A, Romeo S. Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S76-s93. https:\/\/doi.org\/10.3350\/cmh.2024.0438.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"486_CR213","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.54152","volume":"9","author":"L Lei","year":"2026","unstructured":"Lei L, Wang B, Zhao L, Li J, Yan X, Jiang J, et al. Berberine and adiposity in diabetes-free individuals with obesity and MASLD: a randomized clinical trial. JAMA Netw Open. 2026;9(1):e2554152. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.54152.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"486_CR214","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/s2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, Cusi K, Fern\u00e1ndez Land\u00f3 L, Bray R, Brouwers B, Rodr\u00edguez \u00c1. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393\u2013406. https:\/\/doi.org\/10.1016\/s2213-8587(22)00070-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"486_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42162-0","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Li H, Zhang H, Chen X, Chen J, Xu Z, et al. ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, a randomized, placebo-controlled phase Ib\/IIa trial. Nat Commun. 2023;14(1):6409. https:\/\/doi.org\/10.1038\/s41467-023-42162-0.","journal-title":"Nat Commun"},{"issue":"1","key":"486_CR216","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","volume":"18","author":"S Francque","year":"2021","unstructured":"Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour JF, et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol. 2021;18(1):24\u201339. https:\/\/doi.org\/10.1038\/s41575-020-00366-5.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"486_CR217","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","volume":"16","author":"L Geng","year":"2020","unstructured":"Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020;16(11):654\u201367. https:\/\/doi.org\/10.1038\/s41574-020-0386-0.","journal-title":"Nat Rev Endocrinol"},{"key":"486_CR218","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.184396","author":"SH Park","year":"2024","unstructured":"Park SH, Fadhul T, Conroy LR, Clarke HA, Sun RC, Wallenius K, et al. Knockdown of ketohexokinase versus inhibition of its kinase activity exert divergent effects on fructose metabolism. JCI Insight. 2024. https:\/\/doi.org\/10.1172\/jci.insight.184396.","journal-title":"JCI Insight"},{"issue":"2","key":"486_CR219","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100217","volume":"3","author":"EL Shepherd","year":"2021","unstructured":"Shepherd EL, Saborano R, Northall E, Matsuda K, Ogino H, Yashiro H, et al. Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis. JHEP Rep. 2021;3(2):100217. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100217.","journal-title":"JHEP Rep"},{"issue":"1","key":"486_CR220","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1021\/acs.jmedchem.5c02896","volume":"69","author":"ZA Kasun","year":"2026","unstructured":"Kasun ZA, Liang X, Ferrao RD, Kaplan JA, Clark CT, Neubig ME, et al. The Discovery of GS-1291269: A Neutral Ketohexokinase (KHK) Inhibitor with an Unusual Thietane Amine Functional Group. J Med Chem. 2026;69(1):501\u201316. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02896.","journal-title":"J Med Chem"},{"issue":"5","key":"486_CR221","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","volume":"127","author":"S Fiorucci","year":"2004","unstructured":"Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology. 2004;127(5):1497\u2013512. https:\/\/doi.org\/10.1053\/j.gastro.2004.08.001.","journal-title":"Gastroenterology"},{"issue":"5","key":"486_CR222","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/hep.22519","volume":"48","author":"YD Wang","year":"2008","unstructured":"Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008;48(5):1632\u201343. https:\/\/doi.org\/10.1002\/hep.22519.","journal-title":"Hepatology"},{"key":"486_CR223","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(18)30925-5","author":"G Budas","year":"2018","unstructured":"Budas G, Wu F, Turner S, Zagorska A, Li L, Breckenridge D. Characterization of ASK1 signaling in human NASH liver and human hepatic stellate cells. J Hepatol. 2018. https:\/\/doi.org\/10.1016\/s0168-8278(18)30925-5.","journal-title":"J Hepatol"},{"issue":"3","key":"486_CR224","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/jgh.16087","volume":"38","author":"Q Chen","year":"2023","unstructured":"Chen Q, Guo J, Qiu T, Zhou J. Mechanism of ASK1 involvement in liver diseases and related potential therapeutic targets: a critical pathway molecule worth investigating. J Gastroenterol Hepatol. 2023;38(3):378\u201385. https:\/\/doi.org\/10.1111\/jgh.16087.","journal-title":"J Gastroenterol Hepatol"},{"key":"486_CR225","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155589","author":"Y Fujinaga","year":"2020","unstructured":"Fujinaga Y, Kawaratani H, Kaya D, Tsuji Y, Ozutsumi T, Furukawa M, et al. Effective combination therapy of Angiotensin-II receptor blocker and Rifaximin for hepatic fibrosis in rat model of nonalcoholic steatohepatitis. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21155589.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"486_CR226","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","volume":"14","author":"GR Gibson","year":"2017","unstructured":"Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491\u2013502. https:\/\/doi.org\/10.1038\/nrgastro.2017.75.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"486_CR227","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/sj.ejcn.1602127","volume":"59","author":"CA Daubioul","year":"2005","unstructured":"Daubioul CA, Horsmans Y, Lambert P, Danse E, Delzenne NM. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr. 2005;59(5):723\u20136. https:\/\/doi.org\/10.1038\/sj.ejcn.1602127.","journal-title":"Eur J Clin Nutr"},{"issue":"4","key":"486_CR228","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","volume":"58","author":"MR Bomhof","year":"2019","unstructured":"Bomhof MR, Parnell JA, Ramay HR, Crotty P, Rioux KP, Probert CS, et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr. 2019;58(4):1735\u201345. https:\/\/doi.org\/10.1007\/s00394-018-1721-2.","journal-title":"Eur J Nutr"},{"issue":"6","key":"486_CR229","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jhep.2021.12.003","volume":"76","author":"JS Bajaj","year":"2022","unstructured":"Bajaj JS, Ng SC, Schnabl B. Promises of microbiome-based therapies. J Hepatol. 2022;76(6):1379\u201391. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.003.","journal-title":"J Hepatol"},{"issue":"6","key":"486_CR230","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.clnu.2024.04.004","volume":"43","author":"Y Yang","year":"2024","unstructured":"Yang Y, Yang L, Wu J, Hu J, Wan M, Bie J, et al. Optimal probiotic combinations for treating nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Clin Nutr. 2024;43(6):1224\u201339. https:\/\/doi.org\/10.1016\/j.clnu.2024.04.004.","journal-title":"Clin Nutr"},{"key":"486_CR231","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1362694","volume":"11","author":"AS Silva-Sperb","year":"2024","unstructured":"Silva-Sperb AS, Moraes HA, Barcelos STA, de Moura BC, Longo L, Michalczuk MT, et al. Probiotic supplementation for 24\u2009weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial. Front Nutr. 2024;11:1362694. https:\/\/doi.org\/10.3389\/fnut.2024.1362694.","journal-title":"Front Nutr"},{"issue":"11","key":"486_CR232","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41575-020-0344-2","volume":"17","author":"KS Swanson","year":"2020","unstructured":"Swanson KS, Gibson GR, Hutkins R, Reimer RA, Reid G, Verbeke K, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020;17(11):687\u2013701. https:\/\/doi.org\/10.1038\/s41575-020-0344-2.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"486_CR233","doi-asserted-by":"publisher","DOI":"10.3390\/nu16091300","author":"A Mantri","year":"2024","unstructured":"Mantri A, K\u00f6hlmoos A, Schelski DS, Seel W, Stoffel-Wagner B, Krawitz P, et al. Impact of synbiotic intake on liver metabolism in metabolically healthy participants and its potential preventive effect on metabolic-dysfunction-associated fatty liver disease (MAFLD): a randomized, placebo-controlled, double-blinded clinical trial. Nutrients. 2024. https:\/\/doi.org\/10.3390\/nu16091300.","journal-title":"Nutrients"},{"issue":"6","key":"486_CR234","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","volume":"158","author":"E Scorletti","year":"2020","unstructured":"Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, et al. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology. 2020;158(6):1597-610.e7. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.031.","journal-title":"Gastroenterology"},{"issue":"1","key":"486_CR235","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):101. https:\/\/doi.org\/10.1038\/s41392-020-0207-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"486_CR236","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.cmet.2023.10.008","volume":"35","author":"PK Luukkonen","year":"2023","unstructured":"Luukkonen PK, Porthan K, Ahlholm N, Rosqvist F, Dufour S, Zhang XM, et al. The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans. Cell Metab. 2023;35(11):1887-96.e5. https:\/\/doi.org\/10.1016\/j.cmet.2023.10.008.","journal-title":"Cell Metab"},{"key":"486_CR237","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","volume":"22","author":"D Lind\u00e9n","year":"2019","unstructured":"Lind\u00e9n D, Ahnmark A, Pingitore P, Ciociola E, Ahlstedt I, Andr\u00e9asson AC, et al. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Mol Metab. 2019;22:49\u201361. https:\/\/doi.org\/10.1016\/j.molmet.2019.01.013.","journal-title":"Mol Metab"},{"issue":"4","key":"486_CR238","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/hep.31609","volume":"73","author":"BA Banini","year":"2021","unstructured":"Banini BA, Kumar DP, Cazanave S, Seneshaw M, Mirshahi F, Santhekadur PK, et al. Identification of a metabolic, transcriptomic, and molecular signature of patatin-like phospholipase domain containing 3-mediated acceleration of steatohepatitis. Hepatology. 2021;73(4):1290\u2013306. https:\/\/doi.org\/10.1002\/hep.31609.","journal-title":"Hepatology"},{"issue":"11","key":"486_CR239","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41587-023-01680-4","volume":"41","author":"D Hendriks","year":"2023","unstructured":"Hendriks D, Brouwers JF, Hamer K, Geurts MH, Luciana L, Massalini S, et al. Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis. Nat Biotechnol. 2023;41(11):1567\u201381. https:\/\/doi.org\/10.1038\/s41587-023-01680-4.","journal-title":"Nat Biotechnol"},{"key":"486_CR240","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fmed.2019.00304","volume":"6","author":"XC Dong","year":"2019","unstructured":"Dong XC. PNPLA3-A potential therapeutic target for personalized treatment of chronic liver disease. Front Med (Lausanne). 2019;6:304\u2013304. https:\/\/doi.org\/10.3389\/fmed.2019.00304.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"486_CR241","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/liv.14411","volume":"40","author":"S Stender","year":"2020","unstructured":"Stender S, Romeo S. HSD17B13 as a promising therapeutic target against chronic liver disease. Liver Int. 2020;40(4):756\u20137. https:\/\/doi.org\/10.1111\/liv.14411.","journal-title":"Liver Int"},{"issue":"3","key":"486_CR242","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2024.100514","volume":"65","author":"Y Ma","year":"2024","unstructured":"Ma Y, Cai H, Smith J, Chu CH, Mercer SE, Boehm S, et al. Evaluation of antisense oligonucleotide therapy targeting Hsd17b13 in a fibrosis mice model. J Lipid Res. 2024;65(3):100514. https:\/\/doi.org\/10.1016\/j.jlr.2024.100514.","journal-title":"J Lipid Res"},{"issue":"4","key":"486_CR243","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","volume":"78","author":"LY Mak","year":"2023","unstructured":"Mak LY, Gane E, Schwabe C, Yoon KT, Heo J, Scott R, et al. A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. J Hepatol. 2023;78(4):684\u201392. https:\/\/doi.org\/10.1016\/j.jhep.2022.11.025.","journal-title":"J Hepatol"},{"issue":"47","key":"486_CR244","doi-asserted-by":"publisher","first-page":"11958","DOI":"10.1073\/pnas.1808576115","volume":"115","author":"C Kubitza","year":"2018","unstructured":"Kubitza C, Bittner F, Ginsel C, Havemeyer A, Clement B, Scheidig AJ. Crystal structure of human mARC1 reveals its exceptional position among eukaryotic molybdenum enzymes. Proc Natl Acad Sci U S A. 2018;115(47):11958\u201363. https:\/\/doi.org\/10.1073\/pnas.1808576115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"486_CR245","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100693","volume":"5","author":"LC Lewis","year":"2023","unstructured":"Lewis LC, Chen L, Hameed LS, Kitchen RR, Maroteau C, Nagarajan SR, et al. Hepatocyte mARC1 promotes fatty liver disease. JHEP Rep. 2023;5(5):100693. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100693.","journal-title":"JHEP Rep"},{"key":"486_CR246","doi-asserted-by":"publisher","unstructured":"Guo Y, Gao Z, LaGory EL, Kristin LW, Gupte J, Gong Y, et al. Liver-specific mitochondrial amidoxime-reducing component 1 (Mtarc1) knockdown protects the liver from diet-induced MASH in multiple mouse models. Hepatol Commun. 2024;8(5). https:\/\/doi.org\/10.1097\/hc9.0000000000000419.","DOI":"10.1097\/hc9.0000000000000419"},{"key":"486_CR247","doi-asserted-by":"publisher","DOI":"10.3390\/nu14204344","author":"A Mahmoudi","year":"2022","unstructured":"Mahmoudi A, Atkin SL, Jamialahmadi T, Banach M, Sahebkar A. Effect of Curcumin on attenuation of liver cirrhosis via genes\/proteins and pathways: a system pharmacology study. Nutrients. 2022. https:\/\/doi.org\/10.3390\/nu14204344.","journal-title":"Nutrients"},{"key":"486_CR248","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155142","volume":"122","author":"J Rani","year":"2024","unstructured":"Rani J, Dhull SB, Rose PK, Kidwai MK. Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective. Phytomedicine. 2024;122:155142. https:\/\/doi.org\/10.1016\/j.phymed.2023.155142.","journal-title":"Phytomedicine"},{"key":"486_CR249","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2020.111188","volume":"194","author":"H Majidzadeh","year":"2020","unstructured":"Majidzadeh H, Araj-Khodaei M, Ghaffari M, Torbati M, Ezzati Nazhad Dolatabadi J, Hamblin MR. Nano-based delivery systems for berberine: a modern anti-cancer herbal medicine. Colloids Surf B Biointerfaces. 2020;194:111188. https:\/\/doi.org\/10.1016\/j.colsurfb.2020.111188.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"486_CR250","doi-asserted-by":"publisher","DOI":"10.3390\/nu14173459","author":"A Koperska","year":"2022","unstructured":"Koperska A, Weso\u0142ek A, Moszak M, Szuli\u0144ska M. Berberine in non-alcoholic fatty liver disease-a review. Nutrients. 2022. https:\/\/doi.org\/10.3390\/nu14173459.","journal-title":"Nutrients"},{"key":"486_CR251","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3593951","volume":"2016","author":"X Wei","year":"2016","unstructured":"Wei X, Wang C, Hao S, Song H, Yang L. The therapeutic effect of Berberine in the treatment of Nonalcoholic Fatty Liver Disease: a meta-analysis. Evid Based Complement Alternat Med. 2016;2016:3593951. https:\/\/doi.org\/10.1155\/2016\/3593951.","journal-title":"Evid Based Complement Alternat Med"},{"key":"486_CR252","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.freeradbiomed.2019.06.019","volume":"141","author":"X Zhu","year":"2019","unstructured":"Zhu X, Bian H, Wang L, Sun X, Xu X, Yan H, et al. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic Biol Med. 2019;141:192\u2013204. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2019.06.019.","journal-title":"Free Radic Biol Med"},{"issue":"20","key":"486_CR253","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1042\/cs20160400","volume":"130","author":"E Vivoli","year":"2016","unstructured":"Vivoli E, Cappon A, Milani S, Piombanti B, Provenzano A, Novo E, et al. NLRP3 inflammasome as a target of Berberine in experimental murine liver injury: interference with P2X7 signalling. Clin Sci (Lond). 2016;130(20):1793\u2013806. https:\/\/doi.org\/10.1042\/cs20160400.","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"486_CR254","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11860-3","volume":"7","author":"Y Sun","year":"2017","unstructured":"Sun Y, Yuan X, Zhang F, Han Y, Chang X, Xu X, et al. Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells. Sci Rep. 2017;7(1):11340. https:\/\/doi.org\/10.1038\/s41598-017-11860-3.","journal-title":"Sci Rep"},{"issue":"11","key":"486_CR255","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/ptr.6171","volume":"32","author":"L Abenavoli","year":"2018","unstructured":"Abenavoli L, Izzo AA, Mili\u0107 N, Cicala C, Santini A, Capasso R. Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res. 2018;32(11):2202\u201313. https:\/\/doi.org\/10.1002\/ptr.6171.","journal-title":"Phytother Res"},{"key":"486_CR256","doi-asserted-by":"publisher","DOI":"10.3390\/nu9091006","author":"V Marin","year":"2017","unstructured":"Marin V, Gazzin S, Gambaro SE, Dal Ben M, Calligaris S, Anese M, et al. Effects of oral administration of Silymarin in a juvenile murine model of non-alcoholic steatohepatitis. Nutrients. 2017. https:\/\/doi.org\/10.3390\/nu9091006.","journal-title":"Nutrients"},{"issue":"12","key":"486_CR257","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","volume":"15","author":"C Wah Kheong","year":"2017","unstructured":"Wah Kheong C, Nik Mustapha NR, Mahadeva S. A randomized trial of Silymarin for the treatment of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2017;15(12):1940-9.e8. https:\/\/doi.org\/10.1016\/j.cgh.2017.04.016.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"486_CR258","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56100544","author":"A Curcio","year":"2020","unstructured":"Curcio A, Romano A, Cuozzo S, Nicola AD, Grassi O, Schiaroli D, et al. Silymarin in combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to improve liver enzymes and blood lipid profile in NAFLD patients. Medicina (Kaunas). 2020. https:\/\/doi.org\/10.3390\/medicina56100544.","journal-title":"Medicina (Kaunas)"},{"issue":"12","key":"486_CR259","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1007\/s10620-018-5268-0","volume":"63","author":"Q Ou","year":"2018","unstructured":"Ou Q, Weng Y, Wang S, Zhao Y, Zhang F, Zhou J, et al. Silybin alleviates hepatic steatosis and fibrosis in NASH mice by inhibiting oxidative stress and involvement with the Nf-\u03baB pathway. Dig Dis Sci. 2018;63(12):3398\u2013408. https:\/\/doi.org\/10.1007\/s10620-018-5268-0.","journal-title":"Dig Dis Sci"},{"key":"486_CR260","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jep.2017.06.030","volume":"208","author":"CX Cui","year":"2017","unstructured":"Cui CX, Deng JN, Yan L, Liu YY, Fan JY, Mu HN, et al. Silibinin capsules improves high fat diet-induced Nonalcoholic Fatty Liver Disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation. J Ethnopharmacol. 2017;208:24\u201335. https:\/\/doi.org\/10.1016\/j.jep.2017.06.030.","journal-title":"J Ethnopharmacol"},{"issue":"4","key":"486_CR261","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.apsb.2019.02.006","volume":"9","author":"Y Liu","year":"2019","unstructured":"Liu Y, Xu W, Zhai T, You J, Chen Y. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with Nonalcoholic Steatohepatitis by regulating CFLAR-JNK pathway. Acta Pharm Sin B. 2019;9(4):745\u201357. https:\/\/doi.org\/10.1016\/j.apsb.2019.02.006.","journal-title":"Acta Pharm Sin B"},{"key":"486_CR262","doi-asserted-by":"publisher","DOI":"10.3390\/nu17030453","author":"D Handu","year":"2025","unstructured":"Handu D, Stote K, Piemonte T. Evaluating bioactive-substance-based interventions for adults with MASLD: results from a systematic scoping review. Nutrients. 2025. https:\/\/doi.org\/10.3390\/nu17030453.","journal-title":"Nutrients"},{"issue":"9","key":"486_CR263","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1007\/s10787-025-01919-3","volume":"33","author":"MM Azar","year":"2025","unstructured":"Azar MM, Shirazinia M, Nematy M, Baradaran Rahimi V, Bateni M, Gheibi FTP, et al. The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial. Inflammopharmacology. 2025;33(9):5583\u201398. https:\/\/doi.org\/10.1007\/s10787-025-01919-3.","journal-title":"Inflammopharmacology"},{"key":"486_CR264","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.120955","volume":"358","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Yin Z, Zhang Y, Wei Y, Zhai Y, Zhao X, et al. Total extract of Folium Rhododendri Daurici alleviate MASLD by regulating PPAR and TNF signaling pathways. J Ethnopharmacol. 2026;358:120955. https:\/\/doi.org\/10.1016\/j.jep.2025.120955.","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"486_CR265","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2023.10.015","volume":"80","author":"V Ratziu","year":"2024","unstructured":"Ratziu V, Hompesch M, Petitjean M, Serdjebi C, Iyer JS, Parwani AV, et al. Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions. J Hepatol. 2024;80(2):335\u201351. https:\/\/doi.org\/10.1016\/j.jhep.2023.10.015.","journal-title":"J Hepatol"},{"issue":"9","key":"486_CR266","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.medj.2024.07.026","volume":"5","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Mastouri M, Zhang Y. Accelerating drug discovery, development, and clinical trials by artificial intelligence. Med. 2024;5(9):1050\u201370. https:\/\/doi.org\/10.1016\/j.medj.2024.07.026.","journal-title":"Med"},{"issue":"3","key":"486_CR267","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/pharmaceutics5030498","volume":"5","author":"YY Tam","year":"2013","unstructured":"Tam YY, Chen S, Cullis PR. Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics. 2013;5(3):498\u2013507. https:\/\/doi.org\/10.3390\/pharmaceutics5030498.","journal-title":"Pharmaceutics"},{"issue":"15","key":"486_CR268","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM. Patisiran: first global approval. Drugs. 2018;78(15):1625\u201331. https:\/\/doi.org\/10.1007\/s40265-018-0983-6.","journal-title":"Drugs"},{"issue":"10","key":"486_CR269","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673\u201394. https:\/\/doi.org\/10.1038\/s41573-020-0075-7.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"486_CR270","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100667","volume":"6","author":"L Zhou","year":"2025","unstructured":"Zhou L, Huang J, Li C, Gu Q, Li G, Li ZA, et al. Organoids and organs-on-chips: recent advances, applications in drug development, and regulatory challenges. Med. 2025;6(4):100667. https:\/\/doi.org\/10.1016\/j.medj.2025.100667.","journal-title":"Med"},{"key":"486_CR271","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-022-00118-6","author":"CM Leung","year":"2022","unstructured":"Leung CM, de Haan P, Ronaldson-Bouchard K, Kim G-A, Ko J, Rho HS, et al. A guide to the organ-on-a-chip. Nat Rev Methods Primers. 2022. https:\/\/doi.org\/10.1038\/s43586-022-00118-6.","journal-title":"Nat Rev Methods Primers"},{"issue":"21","key":"486_CR272","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202105909","volume":"9","author":"Z Li","year":"2022","unstructured":"Li Z, Lin Z, Liu S, Yagi H, Zhang X, Yocum L, et al. Human Mesenchymal Stem Cell-Derived Miniature Joint System for disease modeling and drug testing. Adv Sci (Weinh). 2022;9(21):e2105909. https:\/\/doi.org\/10.1002\/advs.202105909.","journal-title":"Adv Sci (Weinh)"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00486-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00486-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00486-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:50:42Z","timestamp":1780109442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00486-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":272,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["486"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00486-5","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}